Vivos Therapeutics enters $3.3M ATM equity offering with H.C. Wainwright

Vivos Therapeutics, Inc.

Filed ATM offering agreement to sell up to $3,328,881 of common stock through H.C. Wainwright.
Wainwright will receive a 3% cash commission on gross sales proceeds as agent.
Offering terminates upon sale of all shares or earlier termination by either party.
Amended employment agreements for CEO Huntsman and CFO Amman effective Jan 1, 2025 (previously reported).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.